Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial - PubMed
6 hours ago
- #clinical trial
- #haemoadsorption
- #septic shock
- The Tigris trial was a phase 3, open-label, Bayesian, randomized controlled study conducted at 19 US hospitals to assess polymyxin B haemoadsorption in adults with endotoxic septic shock.
- Patients with septic shock requiring vasopressors, multiple organ dysfunction, and endotoxin activity between 0.60–0.89 units were randomized (2:1) to receive two sessions of polymyxin B plus standard care or standard care alone.
- At 28 days, mortality was 39% in the polymyxin B group vs. 45% in controls, with a posterior probability of benefit of 95.3% (adjusted OR 0.67). At 90 days, the probability of benefit was 99.4% (adjusted OR 0.54).
- Serious adverse events occurred in 30% of the polymyxin B group and 22% of controls, with two treatment-related events in the polymyxin B group.
- The study concluded that polymyxin B haemoadsorption was associated with a high probability of reduced mortality at 28 and 90 days in patients with endotoxic septic shock and multiorgan failure.